Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism

Fulvestrant (Faslodex™) is a pure antiestrogen that is effective in treating estrogen receptor-(ER) positive breast cancer tumors that are resistant to selective estrogen receptor modulators such as tamoxifen. Clinical trials investigating the utility of adding fulvestrant to other therapeutics have...

Full description

Bibliographic Details
Main Authors: Edavana, Vineetha K, Penney, Rosalind B, Yao-Borengasser, Aiwei, Williams, Suzanne, Rogers, Lora, Dhakal, Ishwori B, Kadlubar, Susan
Format: Online
Language:English
Published: Springer International Publishing 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841332/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841332/

Similar Items